Merck chooses France for its first M Lab™ collaboration center in Europe Molsheim is now home to Merck Life Science's first M Lab™ collaboration center in Europe. This new center supports pharmaceutical and biotechnology customers from pre-clinical through full-scale production in non-GMP environment. Molsheim site provides biopharmaceutical manufacturers with a shared,…..
FEATURE STORY ● Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy GENE THERAPY ● Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model ● Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9 RARE DISEASES ● Characterization and treatment of congenital thrombotic thrombocytopenic purpura ● Targeting angiogenesis in…..
1eres Journées Polepharma de microbiomique Le cluster de production pharmaceutique Polepharma organise ses premières journées de microbiomique les 9 et 10 avril prochains à l'UFR Santé de l'université de Rouen. Le programme a été co-construit entre académiques, start-up, PME et grands industriels de la pharma présents au sein du premier…..
Imabiotech, a French CRO based in Lille (France) and in Boston (USA), is expanding its range of services. This company is offering innovative imaging services and software to the pharmaceutical research sector. These services are based on histology combined to label free molecular imaging (Quantitative Mass Spectrometry Imaging, QMSI) . This technology…..
RNA science is now translated into new therapies… Last August, the FDA approved the first RNAi therapy, Onpattro®… RNA drugs allow precised silencing or activation of genes… RNA drugs can address a wide range of common and rare diseases… More than 60 rare or common diseases are currently targeted…. BioPharmAnalyses…..
The European Medicine Agency (EMA) is launching a six-month public consultation on its draft ‘ Regulatory Science to 2025’ strategy for a six-month public consultation. This sixty-page document proposes the plan for advancing the Agency’s engagement with regulatory science over the next five to ten years, covering both human and veterinary medicines. The…..
An interview with Régine Rouzier, president of the CRO Cap Research What is the central issue to successfully perform a phase I trial? The success of a phase I study depends on the speed in execution and the excellence and quality of returned work. These are the two fundamental pillars…..
BioPharmAnalyses is happy to announce the release of the first issue of its « BRIEFING ON CART-T CELLS TRIALS » CAR-T cells therapies are at the forefront of innovation in oncology “BRIEFING ON CART-T CELLS TRIALS” provides you with an accurate overview to explore the latest trials in this hot and rapidly evolging…..
The 2018 Nobel Prize in Physiology or Medicine has been jointly awarded to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation. During the 1990s, in his laboratory at the University of California, Berkeley, James P. Allison studied the T-cell protein CTLA-4.…..
A l’occasion de la 7ème journée de la recherche clinique, l’AFCROs, qui regroupe 75 sociétés-membres représentant environ 70% de l’activité dans le domaine de la recherche clinique et épidémiologique, a présenté les chiffres clés de la recherche clinique en France. Cet outil réalisé par les groupes de travail de l’association vise…..